Furthermore, SFN and LSD1 inhibitor combination treatment revealed superior MDA-MB-231 xenograft tumor growth inhibition by enhancing HDAC5-LSD1 axis inhibition and blocking breast cancer growth [2]. This evidence concerns the gene KDM1A and breast carcinoma.